| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 9705 | Lu-DOTA-TOC |
Please inquire for customized filling and bulk quantities.
|
|
Reference standard for 177Lu-DOTA-TOC
|
||
| Molar Mass: 1593.58 (net peptide) | ||
| C65H89LuN14O18S2 | ||
| [321835-55-6] ([177Lu]-DOTA-TOC) | ||
| Colourless to off-white solid packaged in dark glass screw cap vials. | ||
| Purity: ≥ 95 % | ||
|
Certificates:
CoA; MS (identity); HPLC (purity) |
||
|
Chemical Name: Sequence: DOTA(Lu)-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide. |
||
|
Synonymes: natLu-Edotreotide; natLu-SMT487; natLu-DOTA-[Tyr3]octreotide; Lutetium-177Lu, [N-[2-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic(2→7)-disulfidato(3-)]-; Lutetium-177Lu, [N-[[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic(2→7)-disulfidato(3-)]- |
||
|
Literature: Villard L. et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 2012, 30, 1100-1106. |
||
| date of product catalogue issue: 10 May 2017 | ||